Background. Interleukin (IL)-2 increases CD4 T cell counts when combined with antiretroviral therapy (ART). Whether IL-2 alone can increase CD4 cell counts is unknown.
M A J O R A R T I C L E
Interleukin-2 before Antiretroviral Therapy in Patients with HIV Infection: A Randomized Trial (ANRS 119) cell counts has not been fully investigated [23] . In the present randomized study, we assessed whether intermittent therapy with IL-2 but without concomitant ART could increase CD4 cell counts and thereby defer the initiation of ART.
METHODS

Patients.
Eligible patients were asymptomatic HIV-1-infected adults with a CD4 T cell count of 300-500 cells/mL. Patients were antiretroviral naive or had received !6 months of ART and were not currently receiving therapy (a minimum of 6 months of not receiving therapy was required). Major exclusion criteria were primary HIV infection, a history of an AIDSdefining event, any malignancy within the past 5 years, pregnancy, and previous treatment with interferon or other immunomodulators. Patients were required to have blood cell counts and serum chemistry values within acceptable ranges.
Study design. The study was a multicenter, randomized, 96-week open-label trial conducted at 29 Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) sites in France. The protocol was approved by the ethics committee of Paris Saint-Louis. All patients provided written informed consent. Patients were randomly assigned 1:1 to intermittent IL-2 therapy or to no treatment. In the IL-2 arm, patients underwent 3 cycles of 4.5 MIU of recombinant IL-2 (aldesleukin; Chiron) subcutaneously twice a day for 5 consecutive days at weeks 0, 8, and 16. A fourth cycle could be performed at week 24 if the CD4 cell count increase from baseline was !100%. After week 48, patients whose CD4 cell counts fell below 1.2 times the baseline value could receive up to 2 additional cycles of IL-2 per year. To alleviate IL-2-related adverse events, patients were prescribed, starting on day 1 of each IL-2 cycle, paracetamol, a proton-pump inhibitor, and an antihistaminic drug. Also, IL-2 dose modifications in decrements of 1.5 MIU were allowed in the case of clinical or laboratory toxicities.
Study monitoring. Patients were assessed at baseline and every 8 weeks thereafter. At each visit, clinical data were collected, a physical examination was performed, and a blood specimen was obtained. Routine analyses were performed at each site throughout the follow-up period and included a complete blood count, a CD4 cell count, measurement of plasma HIV-1 RNA level (lower limit of detection, 50 copies/mL), and tests of liver, kidney, muscle, and pancreatic function. When a CD4 cell count of !300 cells/mL was measured at a visit, a second blood specimen had to be drawn 2 weeks later for confirmation of immunologic failure.
An immunologic substudy was conducted in 50 patients. Phenotyping of naive (CD45RA + CCR7 + ), central memory (CD45RA Ϫ CCR7 + ), effector memory (CD45RA Ϫ CCR7 Ϫ ), and effector (CD45RA + CCR7 Ϫ ) CD4 and CD8 T cells was performed at baseline and week 24 by flow cytometry, as described elsewhere [24] . HIV-specific CD4 and CD8 T cell responses were assessed using an interferon-g enzyme-linked immunospot assay, as described elsewhere [25] .
Health-related quality of life was assessed at baseline and at weeks 24, 48, and 96 by means of the self-reporting, 36-item, short-form instrument from the Medical Outcome Study HIV (MOS-HIV) health survey [26] . Safety was assessed through the reporting of adverse events and laboratory abnormalities, the severity of which was assessed by means of the ANRS toxicity grading scale.
Study end points. The primary study end point was a composite of the following events through week 96: a confirmed drop in CD4 cell count to !300 cells/mL, the initiation of ART for any reason, the occurrence of an AIDS-defining event, or death. The primary end point was considered to have been reached when any of these events occurred. Once the primary end point was reached, the initiation of ART was recommended for those in whom it was not already started, and the patient continued to be followed up until study completion, in accordance with the protocol requirement. Secondary outcomes included changes from baseline in CD4 and CD8 T cell counts, changes in plasma HIV-1 RNA levels, the proportion of patients with an AIDS-defining clinical event [27] , the proportion of patients who died, changes in quality of life, and time to ART initiation. Safety end points included the proportions of patients with grade 3 or 4 adverse events and laboratory abnormalities. An independent data and safety monitoring board (DSMB) monitored safety and efficacy data throughout the study. At its fourth meeting in April 2006, following the report of 4 cases of lymphoma, the DSMB recommended that IL-2 therapy be discontinued and that follow-up be extend for 1 year after the completion of 96 weeks. This recommendation was endorsed by the scientific committee of the trial, and patients were asked to provide written informed consent for this extended follow-up.
Statistical analysis. The primary efficacy analysis was to compare between the 2 study arms the crude proportions of patients who reached the composite primary study end point through 96 weeks. All except 2 patients who underwent randomization were included in the analysis; 1 refused the allocated treatment arm and withdrew consent, and 1 violated the inclusion criteria and was taking ART at baseline. All analyses were performed on an intention-to-treat basis.
Our primary hypothesis was that IL-2 therapy would reduce progression to the primary study end point over 96 weeks. The sample size was calculated to detect a 25% absolute difference in the proportion of patients who progressed between the 2 study arms. On the basis of a predicted progression rate of 50% in the control arm, a total of 65 patients per group were required to detect such a difference with a 2-sided a level of .05 and statistical power of 80%. The patient who withdrew consent before day 0 was disappointed by his randomization group, did not start the assigned treatment strategy, and was not included in the analysis. The patient in the interleukin (IL)-2 arm who was receiving antiretroviral therapy (ART) admitted he was taking ART after we noted that his plasma human immunodeficiency virus type 1 RNA level was !50 copies/mL at baseline, and he was also excluded from the analysis. The 1-year extended follow-up surveillance was proposed to all patients after week 96, and those who chose to participate provided a new informed-consent form. Patients who did not complete extended follow-up by 21 February 2008 were censored in Kaplan-Meier analyses. The x 2 test or Fisher's exact test was used to compare categorical variables between the study arms. Differences in continuous variables between study arms were analyzed by the nonparametric Wilcoxon rank-sum test, and the Wilcoxon signed-rank test was used for comparisons within study arms. Changes in CD4 and CD8 T cell counts and in plasma HIV-1 RNA levels were analyzed by censoring data at the time of ART initiation. Comparisons were made using a 2-sided a level of .05 except when multiple significance tests were performed, in which case the Bonferroni correction was used to adjust the significance level.
Time to progression to the primary end point and time to ART initiation were analyzed by the Kaplan-Meier method using data collected up to 21 February 2008. Study arms were compared using a log-rank test.
To identify baseline predictors of progression to the primary end point, univariate and multivariate analyses were performed with the following covariates included in Cox models: age, sex, treatment arm, CD4 cell count, and plasma HIV-1 RNA level. Kaplan-Meier analyses were performed to further define the relationship between baseline plasma HIV-1 RNA level and progression to the primary end point. A cutoff of 4.5 log 10 copies/mL, which was close to the median, was used for clinical relevance in these post-hoc stratified analyses.
Statistical analysis was performed using SAS software (version 9.1; SAS Institute).
RESULTS
Population. From December 2003 through December 2004, a total of 168 patients underwent screening procedures; 130
were found to be eligible for randomization into the study, 2 of whom were excluded from the analysis (figure 1). The baseline characteristics of the remaining 128 patients were well balanced between the study arms (table 1). In the IL-2 arm, all patients received IL-2 and 89% ( ) received 4 cycles durn p 58 ing the first year, with a mean IL-2 dose per cycle of 43.7 MIU. Fifty-two percent of patients ( ) and 6% ( ) received n p 34 n p 4 at least 1 and at most 2 additional cycles during the second and third years, respectively. Overall, 121 patients (95%) completed 96 weeks of follow-up, and 100 patients (77%) completed the extended follow-up.
Study outcomes. Through 96 weeks, 23 (35%) of 65 patients in the IL-2 arm and 37 (59%) of 63 patients in the control arm reached the protocol-defined composite primary end point ( ). Reasons included immunologic failure (18 in the P p .008 IL-2 arm and 28 in the control arm), initiation of ART (4 in the IL-2 arm and 6 in the control arm, for CD4 cell count decline or thrombocytopenia), AIDS-related events (2 cases of tuberculosis in the control arm), and death (1 in each arm). Time to the primary end point was significantly shorter in the control arm ( figure 2A ), which had a relative risk of 2.11 (95% confidence interval, 1.3-3.6) compared with the IL-2 arm. Once the primary end point was reached, the median time to ART initiation was 7.4 weeks in the control arm and 11.8 weeks in the IL-2 arm ( ). P p .63 Figure 3 shows the median changes from baseline in CD4 cell counts for both groups throughout the study. At week 24 (after 3 cycles of IL-2), median changes from baseline in CD4 cell counts were + 83 and Ϫ23 cells/mL in the IL-2 and control arms, respectively ( ). At week 96, median changes from P ! .001 baseline in CD4 cell counts were +51 and Ϫ64 cells/mL in the IL-2 and control arms, respectively ( ). P ! .001 Among patients enrolled in the immunologic substudy, median changes from baseline at week 24 were +19, +59, +20, and Ϫ9 for naive, central memory, effector memory, and effector CD4 cells in the IL-2 arm, respectively, compared with Ϫ29, Ϫ15, +20, and Ϫ13 in the control arm ( and P p .024 for naive and central memory subsets). There was no P p .035 significant change in the proportion of patients with HIV-specific CD4 or CD8 cells between study arms (data not shown).
No significant change from baseline in CD8 cell count was noted through week 96 for either arm. Similarly, median plasma HIV-1 RNA levels in both study arms remained unchanged throughout the study ( figure 3B) . At week 96, median changes from baseline in plasma HIV-1 RNA level were +0.02 and +0.04 log 10 copies/mL in the IL-2 and control arms, respectively ( ). P p .92
By means of Cox models, baseline CD4 cell count, baseline plasma HIV-1 RNA level, and treatment arm were identified as independent predictive factors of progression to the primary study end point (table 2) . However, a significant ( ) P p .01 interaction between treatment arm and plasma HIV-1 RNA level was detected in the model. Although CD4 cell count was the only covariate associated with progression in the control arm, both CD4 cell count and plasma HIV-1 RNA level were found to be associated with progression in the IL-2 arm. Stratified Kaplan-Meier analyses were therefore performed to further estimate the risk of progression to the primary end point according to baseline plasma HIV-1 RNA level. Among patients with a plasma viral load !4.5 log 10 copies/milliliter, Kaplan-Meier estimates (95% confidence intervals) of the probability of remaining free of progression to the primary end point through week 150 were 0.64 (0.47-0.77) and 0.10 (0.02-0.26) in the IL-2 and control arms, respectively ( ) ( figure 2B ). P ! .001 Also, the probability of not initiating ART was 0.75 (0.58-0.86) in the IL-2 arm and 0.19 (0.06-0.36) in the control arm ( ) among patients with a baseline plasma HIV-1 RNA P ! .001 level !4.5 log 10 copies/milliliter ( figure 2C) , with an observed delay of 92 weeks for ART initiation in the IL-2 arm. Among patients in the higher HIV-1 RNA stratum, the differences in either time to progression or time to ART initiation were not statistically significant between the 2 study arms (figure 2B and 2C). by the log-rank test for the comparison between P ! .001 IL-2 therapy and no treatment among patients with a plasma HIV-1 RNA level !4.5 log 10 copies/mL at baseline. C, Kaplan-Meier estimates of the likelihood of not initiating ART, stratified by baseline plasma HIV-1 RNA level. Data through 21 February 2008 are reported. The intention-to-treat analysis revealed by the log-rank test for the comparison between IL-2 therapy and P ! .001 no treatment among patients with a plasma HIV-1 RNA level !4.5 log 10 copies/ mL at baseline. Among patients with a baseline HIV-1 RNA level !4.5 log 10 copies/mL, the first quartile (Q1) time to ART initiation was deferred by 92 weeks in patients receiving IL-2.
During overall follow-up, 5 patients (8%) in the control arm and 6 (9%) in the IL-2 arm progressed to AIDS or death, with all events occurring within the first 96 weeks ( ). In the P p .79 control arm, 2 patients died (1 of an unspecified cause and 1 of septic shock after the onset of non-Hodgkin lymphoma), and 3 experienced an AIDS-defining event (2 cases of tuberculosis and 1 of oesophageal candidiasis). In the IL-2 arm, 1 patient was murdered, and 5 experienced an AIDS-defining event (1 case of Burkitt lymphoma, 2 of Hodgkin lymphoma, 1 of cutaneous Kaposi sarcoma, and 1 of Pneumocystis jiroveci pneumonia).
Overall, 4 patients developed lymphoma during follow-up-3 in the IL-2 arm and 1 in the control arm ( ). The P p .32 DSMB was concerned by the uneven distribution of the cases and recommended that caution be exercised in discontinuing maintenance IL-2 cycles during the second year of the study and that patient follow-up be extended for another year. After the implementation of this recommendation, no additional cases of lymphoma were reported.
Safety and tolerability. A high number of adverse events were reported during the first 96 weeks of the trial. As expected, they were more frequent in the IL-2 arm ( ) than in n p 1628 the control arm ( ) ( ). However, the vast man p 342 P ! .001 jority of these events were mild (grade 1 or 2). Constitutional symptoms (such as asthenia, fever, nausea, myalgia, insomnia, headache, arthralgia, dizziness, anorexia, and diarrhea) were the most frequent complaints and accounted for 50% of all adverse events (data not shown).
Twenty-four patients (37%) in the IL-2 arm and 15 (24%) in the control arm experienced at least 1 grade 3 or 4 adverse event ( ), with only 7 patients (3 in the IL-2 arm and P p .11 4 in the control arm) experiencing grade 4 events (table 3) . There were, however, more events in the IL-2 arm than in the control arm (50 vs. 22).
These events led to transient IL-2 dose reductions in only 15 patients (23%). Also, 11 patients (17%) in the IL-2 arm and 10 (16%) in the control arm experienced grade 3 or 4 laboratory abnormalities ( ), with a similar number of events in P p .87 each group (16 in the control arm and 14 in the IL-2 arm) (table 3). Only 3 patients experienced a severe non-AIDS-defining event during follow-up (1 case of breast carcinoma and 1 of bladder carcinoma, both in the control arm, and 1 case of transient stroke in the IL-2 arm), with no severe liver or kidney disease.
There was no significant change from baseline in MOS-HIV physical and mental health summary scores through week 96 in either arm of the study. The median changes from baseline in the physical summary score were Ϫ2.57 and Ϫ1.71 points in the IL-2 and control arms, respectively ( ), and the P p .67 median changes from baseline in the mental summary score Figure 3 . A, Median change from baseline in CD4 cell count among patients randomly assigned to intermittent interleukin (IL)-2 therapy or no treatment during the first 96 weeks of the trial (baseline value is the average of measurements made at screening and day 0, and data were censored at the time of antiretroviral therapy [ART] initiation). Differences were tested at weeks 24 and 96 and were found to be statistically significant ( for both comparisons). Bars show interquartile ranges. B, Median change from baseline in log 10 plasma human immunodeficiency virus type P ! .001 1 (HIV-1) RNA level among patients randomly assigned to intermittent IL-2 therapy or no treatment during the first 96 weeks of the trial (data are censored at the time of ART initiation). Box plots show interquartile ranges and fifth and 95th percentiles.
were Ϫ0.01 and +2.45 points in the IL-2 and control arm, respectively ( ). P p .86
DISCUSSION
The present study has demonstrated that, among asymptomatic HIV-infected patients who were mostly ART naive and who had CD4 cell counts of 300-500 cells/mL, intermittent subcutaneous IL-2 therapy in the absence of ART was able to induce a significant and sustained increase in CD4 cell count without affecting plasma HIV replication, thereby allowing ART initiation to be deferred.
Indeed, after 96 weeks of follow-up a median increase from a baseline CD4 cell count of 51 cells/mL was seen in the IL-2 arm, whereas a decrease of 64 cells/mL was observed in the control arm ( ). These results therefore confirm and P ! .001 extend those of the UK-Vanguard study and show that intermittent IL-2 therapy alone is able to increase CD4 cell counts in patients in the early stages of HIV infection [23] . However, this increase in the CD4 cell count was less striking than that in patients receiving IL-2 therapy with concomitant ART, in whom increases of 1200 cells/mL are usually seen [16] [17] [18] 28] . The reasons for this blunted CD4 cell response are presently unclear, but persistent viral replication seems to be the most likely explanation, as was recently reported [29] . Of note, IL-2 did not increase viral replication in the present study and had no effect on HIV-specific immunity. a First-order interactions between treatment, CD4 cell count, and plasma HIV-1 RNA levels were investigated. Only the interaction between treatment and plasma HIV-1 RNA level was statistically significant ( ); therefore, HRs for progression to the primary end point were estimated for each arm P p .01 separately.
Phenotypic analyses of CD4 cell subsets in our study demonstrated a preferential increase in naive and central memory CD4 cell populations in the IL-2 arm, similar to what has been reported when IL-2 is combined with ART and which seem to be critical to the prevention of disease progression in animal models [29] [30] [31] .
IL-2 therapy successfully reduced the rate of progression to the primary end point (defined as a confirmed drop in CD4 cell count to !300 cells/mL, the initiation of ART for any reason, the occurrence of an AIDS-defining event, or death). Indeed, rates of progression through week 96 were 35% in the IL-2 arm versus 59% in the control arm ( ). Interestingly P p .008 enough, the baseline plasma HIV-1 RNA level, which was not associated with progression in the control arm (as previously reported [32] ), was the best predictor of progression in the IL-2 arm. This finding allowed us to identify a subgroup of patients with relatively low plasma HIV-1 RNA levels who benefited most from IL-2 therapy. Indeed, among patients with a plasma HIV-1 RNA level !4.5 log 10 copies/mL, the estimated probability of nonprogression through week 150 was 64% in the IL-2 arm, compared with only 10% in the control arm ( ); P ! .001 as a consequence, there was a 92-week delay in the initiation of ART in the IL-2 arm. Also, the probability of not initiating ART through week 150 was 75% in the IL-2 arm, compared with 19% in the control arm ( ) ( figure 2C) . These strik-P ! .001 ing differences suggest that IL-2 therapy could maintain high CD4 cell counts for prolonged periods in a subgroup of asymptomatic patients with a low level of viral replication, thus preventing HIV-induced immune deficiency. The mechanisms by which IL-2 exerts its activity deserve further investigation, but they are likely to be related to the role it plays in immune activation and CD4 T cell survival [33] . Of note, this benefit of IL-2 without ART was not seen in the long-term follow-up of the UK-Vanguard study, and we have no clear explanation for this discrepancy [34] .
The tolerability of IL-2 therapy in this trial was acceptable and was similar to that in previous reports-we observed a high number of low-grade events, which were mostly constitutional symptoms that led to dose reduction or treatment discontinuation in only a limited number of patients. Also, quality-of-life assessments showed no significant effect of IL-2 therapy over 96 weeks. Our choice of a relatively low dose of IL-2 (4.5 MIU twice daily for 5 days) with 4 fixed cycles the first year and only 1 to 2 optional cycles per year thereafter seems, therefore, to be an acceptable design that will allow a long-term treatment strategy at a reasonable cost [35] .
However, the clinical benefit, if any, of the use of IL-2 in patients without ART remains to be assessed, especially after 2 large international trials of IL-2 in addition to ART failed to demonstrate such a benefit [36, 37] . Moreover, the occurrence of 4 cases of lymphoma during our study is a concern and led the DSMB to halt the trial, although data from clinical trials and cohorts of patients receiving IL-2 therapy in addition to ART have not reported such an association [36] [37] [38] . Our study was indeed not powered to demonstrate a clinical benefit of this strategy. Only 11 patients (5 in the control arm and 6 in the IL-2 arm) experienced an AIDS-defining event or death during follow-up. However, as patients were asked to start ART (17) .87
Total no. of events 16 14 NOTE. Adverse events were judged to be possibly, probably, or definitely related to the study medication. Subjects were counted only once, even if they had 2 or more episodes of the same adverse event. Severity was assessed according to the Agence Nationale de Recherches sur le SIDA et les Hé patites Virales toxicity grading scale. ULN, upper limit of normal.
once their CD4 cell counts dropped to !300 cells/mL in both study arms, one should not expect a strategy of using IL-2 before ART to decrease the occurrence of AIDS-defining events but rather to be able to safely defer the time to ART initiation without increasing the risk of opportunistic events. In this respect, the lack of clinical benefit seen in the ESPRIT (Evaluation of Subcutaneous Proleukin in a Randomized International Trial) and SILCAAT (Subcutaneous, Recombinant, Human IL-2 in HIV-Infected Patients with Low CD4 Counts under Active Antiretroviral Therapy) studies in patients receiving IL-2 plus ART is not relevant to our strategy of using IL-2 without ART [36, 37] .
Although the constraints of ART have been alleviated by the availability of once-daily dosing schedules, a reduced pill burden, and the better safety and tolerability of new regimens, it remains important to assess whether immune-based strategies could safely defer the use of ART for years in some patients. Obviously, the clinical safety of such a strategy should be carefully assessed through adequately powered clinical trials before implementation. Also, it should be remembered that suppressing HIV replication by means of ART could reduce the risk of serious non-AIDS events and of HIV transmission, and this should also be addressed in future trials [4] .
Larger trials targeting a population of asymptomatic patients with high CD4 cell counts and a low level of plasma HIV replication should therefore be considered. These trials should be long enough to assess the long-term clinical benefits and safety of this strategy. Other cytokines, such as IL-7, could also be tested in this setting, given that they may have a better tolerability profile [39] .
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